Comparison · NCT05288504-038e1166
AVTX-002 vs Placebo: The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience Asthma Related Events.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AVTX-002 vs Placebo: The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience Asthma Related Events. Trial comparisons, record NCT05288504-038e1166. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05288504-038e1166
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.267 | 0.16 | 0.41 | wilson | |
| Risk in group 2 | 0.311 | 0.195 | 0.457 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0444 | -0.225 | 0.14 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.857 | 0.447 | 1.64 | log | |
| Odds ratio, group 1 over group 2 | 0.805 | 0.323 | 2.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on AVTX-002 than on Placebo | 22.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AVTX-002 | AVTX-002: Dose of 600 mg administered subcutaneously three times during the study. | 12 | 45 | OG000 |
| Group 2 | Placebo | Placebo: Placebo sourced as normal saline administered subcutaneously three times during the study. | 14 | 45 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience Asthma Related Events.
- Description
Percentage of patients who experience any of the following asthma related events:~* ≥6 additional reliever puffs of Short-Acting Beta-Agonist (compared to baseline) in a 24-hour period on 2 consecutive days or,~* increase in inhaled corticosteroid dose ≥4 times than the dose at baseline or,~* a decrease in peak flow of 30% or more (compared to baseline) on 2 consecutive days of treatment, or~* an asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days, or~* a hospitalization or emergency room visit because of an asthma exacerbation
- Time frame
- Through Week 14
- Population
- Full Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
- NCT number
- NCT05288504
- Phases
- PHASE2
- Conditions
- Non-Eosinophilic Asthma
- Interventions
- AVTX-002, Placebo
- Lead sponsor
- Avalo Therapeutics, Inc.
- Results first posted
- 2024-09-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05288504?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05288504-038e1166